Entinostat
- Generic Name
- Entinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20N4O3
- CAS Number
- 209783-80-2
- Unique Ingredient Identifier
- 1ZNY4FKK9H
- Background
Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic Therapy.
- Indication
联合芳香化酶抑制剂用于治疗激素受体（HR）阳性、人类表皮生长因子受体-2（HER-2）阴性，经内分泌治疗复发或进展的局部晚期或转移性乳腺癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Registration Number
- NCT03760614
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Roberto Pili
- Target Recruit Count
- 18
- Registration Number
- NCT03552380
- Locations
- 🇺🇸
Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Georgetown University, Washington, District of Columbia, United States
Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Taizhou EOC Pharma Co., Ltd.
- Target Recruit Count
- 375
- Registration Number
- NCT03538171
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy Medical Sciences, Beijing, Beijing, China
High Dose IL 2 and Entinostat in RCC
- Conditions
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Roberto Pili
- Target Recruit Count
- 46
- Registration Number
- NCT03501381
- Locations
- 🇺🇸
Univeristy of Southern California, Los Angeles, California, United States
🇺🇸Hematology Oncology Clinic, LLC, Baton Rouge, Louisiana, United States
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 13
- Registration Number
- NCT03473639
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
- Conditions
- Interventions
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT03361800
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States
Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 133
- Registration Number
- NCT03291886
- Locations
- 🇯🇵
Tsukuba University Hospital, Tsukuba, Ibaraki, Japan
🇯🇵National Cancer Center Hospital, Chuo, Tokyo, Japan
🇯🇵Toranomon Hospital, Minato, Tokyo, Japan
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 138
- Registration Number
- NCT03280563
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2024-01-09
- Target Recruit Count
- 44
- Registration Number
- NCT03250273
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT03215264
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.